HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Relay Therapeutics (NASDAQ:RLAY) but lowers the price target from $20 to $18.
July 17, 2024 | 10:22 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Relay Therapeutics but lowers the price target from $20 to $18.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100